Our proprietary platform enables us to develop safer and more effective active ingredients for next-generation medical products and treatments. Our disruptive patented compounds are licensed
by pharmaceutical companies worldwide.
FSE: ZSB | OTC: SRBCF
Howard J. Verrico, MD
Founder, Sirona Biochem
CEO and Chairman of the Board
Welcome to Sirona Biochem
Sirona Biochem’s strategy is to license or sell patented compounds to leading global companies in return for up-front fees, milestone fees and ongoing royalty payments.
I'm delighted to announce that Sirona Biochem has signed a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, for TFC-1067.
Our Investor's Presentation provides a clear overview of Sirona Biochem, its operations, technology and other information relevant to prospective investors.
TSX Venture Exchange
Frankfurt Stock Exchange
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery firm with a proprietary technology. Through its wholly-owned French Subsidary TFChem, the Company specialises in stabilising carbohydrate moleclues with the goal of improving efficiacy and safety.
Our world class team is comprised of award winning scientists who have worked for Fortune 500 companies such as Sanofi, GSK and Bayer.
Geraldine Deliencourt-Godefroy, PhD
Chief Scientific Officer
Our Proprietary Technology
Sirona's Flourination Chemistry Technology is the solution to unstable carbohydrate molecules.
The chemistry strengthens the bond of a carbohydrate molecule by strategically placing flourine atoms.
Our technology has received more than $8M CAD in grants from the French Government
Sirona has 83 approved and pending patents globally.